FAQ: Hormone Therapy for F2M Transsexuals

Abstract

This document contains a list of frequently asked questions and their answers regarding hormone therapy (secondary sexual reassignment) for female-to-male transsexuals. More generally, this document contains information about gonadal hormones and anti-hormones, so it can be a helpful reference for the treatment of androgen and estrogen-sensitive conditions--for example, certain cancers of the reproductive organs and breasts.

Sponser Advertizement Space

The hormone faq is viewed or scanned about 7,000 times per week. To help offset research and publishing costs, for U.S. $20/month, or $100/6 months, you can rent billboard/link space in the F2M or M2F version of this document to advertize certain directories, services or products to transsexuals. Contact confluence at savina dot com (Confluence Publications).

The authoritative location of this document is:

http://www.savina.com/confluence/hormone/f2m/

Hypertext.

http://www.savina.com/confluence/hormone/f2m/flat.htm

Large (~164kb) flat file suitable for download and offline browsing.

Ftp service has been discontinued due to the relatively low demand (less than 0.5% of web traffic) and the inconvenience of maintaining asciified tables.

Each page in this document has a footer displaying the date of the most recent change.

Please send additions, corrections, and suggestions to confluence at savina dot com.

Copyright and Terms of Redistribution

Contents copyright ¿ 1994-1998 by confluence at savina dot com (Confluence Publications). Permission is granted to freely redistribute, provided that:

• The entire document from first line of header to last line of footer is reproduced unabridged, unedited (except for layout format) and you notify Confluence Publications, or;
• Less than 20 lines are quoted to answer a specific question, and the authoritative location of this document is specified in addition to the quote.
• Redistribution of the web version must be via a faithful mirror of all document components, updated monthly. Other public cybernetic redistribution must also be updated monthly. This will help ensure that the latest, safest information is available to those who seek it. This document is hosted on a stable server with fast, redundant network connections. You are strongly encouraged to link directly to http://www.savina.com/confluence/hormone/f2m/ instead of redistributing a copy.
• The republished document or quote is made available without charge (beyond a nominal charge for accessing e-mail, public net news, public web sites, and non-profit support groups). Hardcopy or cybernetic redistribution of any portion for profit requires negotiation with Confluence Publications.

All other rights are reserved.

Disclaimers

The answers in this document are collected from a variety of sources: medical literature, pharmaceutical company advertizement, verbal advice of medical doctors, second-hand anecdotes, and personal experience. Despite the authoritative tone of this document, it is presented for educational interest only, not direct advice. It contains opinions, sweeping generalizations, and at least one mistake. The author is not a medical doctor, and makes no claim or warranty as to the suitability of the information in this document for application to any particular individual. YOU, the reader, take sole responsibility for interpretation and application of this information. Form your own opinions by doing your own research. May your favorite deity curse you if you seriously consider sueing the author for misinforming you.

The endocrine feedback system is intricate, delicate, and poorly understood. Even the experts do not entirely agree on how to best meddle with it. Hormone therapy is fraught with risk as well as promise. Be sure you have fully considered the implications before you start. Work with a medical doctor who is qualified to interpret your signs, symptoms, blood tests, and development in the context of your personal medical history. Do not take hormones that you did not obtain directly from a licensed pharmaceutical distributor; the quality of drugs obtained through other channels is not only suspect, but possibly dangerous--especially those in injectable form.

Notes

• The words "female" and "male" refer to the original physical form, not to gender identification.
• This document does not address hormone therapy of the individual with an endocrine system disorder.
• Pre-op hormone dosages are determined mainly from verbal advice of medical doctors, second-hand anecdotes, and personal experience.
• Post-op hormone dosages are determined mainly from the Physician's Desk Reference (PDR) according to the recommendation of hormone replacement of normal gonadal hormone production.
• Drugs are ranked by the following criteria:
  1. Safety and efficacy: excellent, good, fair, unknown, or poor. This is based on normal indications (i.e., when the primary indication is male hormone replacement, it is suitable for transsexual hormone therapy), delivery method (sustained-release injectibles and transdermal films are easier on the liver than oral tablets), literature, medical doctor advice, anecdotes, and other factors noted in the individual hormone comment field. Safety and efficacy are generally closely linked, so the ranking is combined.
• Of the injectable hormones and anti-hormones available, only those that are sustained-release (requiring injection less frequently than once per week) are listed.
• The adverse effects listed in this document are gleaned primarily from drug information sheets and the PDR. They are translated from medibabble into English where possible. While this information should not be taken lightly, it should be viewed with slight suspicion, since it is first and foremost advertizement and legal copy from pharmaceutical companies. To attempt to reduce their exposure to lawsuits, they list not only the effects reasonably shown to be caused by the drug during clinical trial(s), but also every other adverse effect that the patients experienced while taking the drug--or any other drug of the same class--whether or not the effect was proven statistically relevant by controlled study for the drug in question. In particular, the reader should not be unduly worried about the mention of increase of body hair and loss of scalp hair from estrogens, nor about increase of body hair and deepening of voice from androgen receptor antagonists and GnRH agonists. Finally, adverse effects are only listed here if they make sense in their application to transsexuals, i.e., adverse effects on uniquely female organs are not listed for drugs intended for male-to-female transsexuals, and vice-versa. One should really read the PDR for the drugs of interest in order to provide context for the adverse effects listed in this document.

Questions Answered in This Document

1. What are hormones, and how do they work?
2. What are normal endogenous androgen and estrogen levels?
3. What effect does contrasexual hormone therapy have, and how soon?
4. What are the popular treatment philosophies?
5. How are hormones delivered?
6. How can the intended effects of hormone therapy be maximized and the dangers minimized?
7. How can one obtain hormones?
8. Exactly what hormones are available? What are the details on popularity, dosage, availability, contraindications, adverse effects, etc.?
9. Where is there more information about hormones?

What Are Hormones, and How Do They Work?

Hormones are long-range chemical messengers of the body, manufactured and controlled by the endocrine system. Hence the title of endocrinologist for hormone doctors.

The hypothalamus produces gonadotropin-releasing hormone (GnRH). This signals the anterior pituitary gland to synthesize and release luteinizing hormone (LH). To a lesser degree, GnRH also triggers the synthesis and release of follicle stimulating hormone (FSH). Subsequently, LH and FSH signal the gonads (ovaries in females, testes in males) to synthesize and release hormones that cause differentiation of the body tissue into female or male form: estrogens, progesterones, and testosterones. A small quantity of testosterones are also produced by the adrenal gland. Proportionally, females have more estrogens and progesterones than males; males have more testosterones.

Estrogens include natural and synthetic estradiols, estrones and estriols. They excite estrogenic receptors, causing the body to differentiate into female form and function. Natural and synthetic estrogens are hereafter referred to simply as estrogens.

Progestogens (or progestins) are synthetic progesterone analogues. Progesterones and progestogens excite progesteronic receptors, which in cooperation with estrogenic activity, cause the body to further differentiate into female form and function. Natural and synthetic progesterones are hereafter referred to simply as progesterones.

Various testosterones are collectively known as androgens. They excite androgenic receptors, causing the body to differentiate into male form and function. Natural and synthetic testosterones are hereafter referred to simply as androgens.

Anti-hormones can be useful in transsexual hormone therapy because they block hormone action or production. The basic mechanisms are:

• Estrogen receptor antagonist: blocks the action of estrogens at certain receptor sites.
• GnRH agonist: briefly overstimulates then effectively suppresses pituitary LH and FSH production.

Aggressive exogenous hormone therapy indirectly reduces endogenous (natural) gonadal hormone production by fooling the pituitary into thinking that there are plenty of hormones already in the body; consequently, the pituitary reduces the LH and FSH signals that stimulate the gonads.

Postnatally administered hormones do not cause development of are opposite those born with. However, postnatal contrasexual hormone therapy does cause development of secondary sex characteristics as described below.

What Are Normal Endogenous Androgen and Estrogen Levels?

The normal endogenous androgen range in a male is 300-1100 nanograms per deciliter. Estrogen is generally below 50 picograms per milliliter.

The normal endogenous androgen range in a female is 10-100 nanograms per deciliter. There are dramatic cyclic and individual variations of estrogen (estradiol + estrone), with 100-400 picograms per milliliter being the most usual, with 25-700 being possible depending on the individual. 400 is considered a nominal "mid-peak" (ovulation) level.

What effect does male hormone therapy have on a female, and how soon?

The longer after puberty hormone therapy is started, the less effective it is--but not a linear scale, e.g., results are considerably more dramatic in an 18 year old than a 28 year old, but results are not on the average dramatically different between a 38 year old and a 48 year old.

The following effects have been observed in varying degrees--anywhere from little to moderate--with extended treatment. With effective and continuous dosages, most of the changes that a particular body is genetically prone to will start with the very first administration of androgens, start becoming irreversible (only the vocal cord thickening) almost immediately, start leveling off somewhat within 2 years, and be mostly done within 5 years. The leveling may take longer if the ovaries are not removed.

• The vocal cords thicken, deepening the voice--although not necessarily all the way down to an average male frequency.
• Fertility decreases. Menstrual cycle becomes irregular then stops.
• Sex drive increases. Sexual enjoyment may also increase, but the clitoris may become so sensitive as to make direct stimulation painful.
• Clitoris elongates, eventually reaching 3-8 cm. The later in life hormones are started, the less pronounced is the elongation.
• Body and facial hair growth speeds up, becomes much thicker, and may darken.
• Male pattern baldness may set in.
• Muscle mass--especially around the shoulders and chest--increases with exercise. It may even increase slightly with no exercise.
• Oil and sweat glands become more active. This may result in acne.
• Fat is redistributed. The face becomes more typically male in shape. Fat tends to move away from the hips and toward the waist.
• Many people also report the following effects, but they are not verified in any medical literature that the author has read:
• Outer skin layer becomes rougher in feeling and appearance.
• Metabolism increases. Given a caloric intake and exercise regimen consistent with pre-hormonal treatment, one tends to lose weight, gain energy, need less sleep, become hot more easily, and feel generally more alert. However, appetite usually increases, so one may gain weight because of increased caloric intake and increased muscle mass.
• Body odors (skin and urine) change. They become less "sweet" or "musky" and become more "tangly" or "metallic."
• Emotions change. Aggressive and dominant feelings may increase.

Male hormones do not:

• Significantly decrease the size of the breasts. However, they may soften somewhat.
• Change the shape or size of bone structure. However, they may change the bone density slightly.

What Are the Popular Treatment Philosophies?

The following androgen dosage philosophies are popular for treatment of female-to-male transsexuals, and are presented in descending order of preference in the humble opinion of the author.

Table 1: Androgen dosage philosophies

		Dosage	Reasoning
1	A	Adjust androgen to achieve a serum androgen level in the normal range of a male; more or less ignore the serum estrogen level	The body cannot make good use of more androgen than a male would naturally generate	Estrogens do not directly compete with androgens for androgen receptor sites	There is a direct correlation between exogenous androgen dosage and adverse effects, especially liver disease
	B	Administer consistently low dosage of androgens
2	A	Adjust androgen to achieve a serum estrogen level in the normal range of a male; more or less ignore the serum androgen level	The body might be able to make good use of more androgen than a male would naturally generate	Estrogens might compete with androgen for androgen receptor sites	High levels of exogenous androgen over a limited period, i.e., less than 3 years, do not usually cause adverse effects in a person with a very healthy liver.
	B	Administer consistently high dosage of androgens

Clearly, philosophy 1 and 2 reasonings flatly contradict each other. There are good endocrinologists in each camp, which demonstrates that we still really do not know exactly how hormones work. However, there is more compelling evidence for the reasoning of philosophy 1. In some people philosophy 1 might have a not have quite as steep of a ramp of results as philosophy 2--but, with patience, the results seem to be just as good. The A philosophies adjust to the body's assimilation of the androgens, whereas the B philosophies assume "one size fits all." Gross empirical results, e.g., beard growth, should be used as a secondary rather than primary indicator. Finally, note that the endogenous level of estrogen in females (F2M) seems to be a less important factor for development than the endogenous level of androgens in males (M2F).

How Are Hormones Delivered?

Table 2: Delivery methods

	Advantages	Disadvantages
Oral	Convenience. Possibly more beneficial for blood cholesterol levels than injections.	Increased stress on the liver since it has to process the hormones twice instead of just once
Injection	Less liver stress than oral delivery. Inexpensive.	Less steady hormone level. Pain and slight infection risk from hypodermic needle usage.
Transdermal film	Less liver stress than oral delivery. Hormone level more steady than injections.	Inconvenience and skin irritation. Multiple simultaneous patches required for pre-op dosage. Expensive. The patches are meant to be applied to a post-surgical genital site.

Note that the absorbtion of oral preparations varies greatly among individuals. With some the absorbtion is poor; in that case, injection or transdermal film is indicated.

Sustained-release intramuscular injectable hormones are suspended in oil. This is the usual procedure for administration:

1. If you are very sensitive to pain, obtain 2 new needles for each administration: 1 to fill the syringe (18-22 guage), and another for the injection (22 guage). That way the injection needle will be entirely sharp. Be careful not to drag the injection needle across anything, even skin, before the injection, because that will dull it.
2. If you are fairly tolerant of pain, or cannot afford 2 needles for each injection, then use the same new needle (22 guage) to fill the syringe as to make the injection. Do not under any circumstances reuse needles between injection periods, or between different people.
3. Warm the vial (ampule) between your hands for a moment to help the oil flow more freely.
4. Cleanse the top of the vial and the area for injection with a swipe of povidone-iodine (10%), or if you cannot obtain that, use rubbing alcohol (95-99%) or hydrogen peroxide (3-5%).
5. The best intramuscular injection sites are the upper outer quadrant of the buttock, or upper outer thigh. Either is fine, as long as you are hitting at least two inches of fat and muscle, not bone or an artery.
6. Securely mount the drawing needle on the syringe, then pull back the plunger about 1/4-1/3 cc farther than the intended injection amount (e.g., if you intend to inject 1 cc, then draw back 1 1/4 - 1 1/3 cc of air).
7. With the vial right-side-up, insert the needle in the top, such that the needle end is in the bottle air, but not the oil. Inject all of the air from the syringe into the vial.
8. Turn everything so the vial is upside-down, be sure the needle end is in oil (not air, and not bumping against the glass), then slowly but firmly draw back the plunger until you have a bit more than the injection amount. You will probably see some small air bubbles; that is normal. Inject the extra solution, along with the top bubble, back into the vial.
9. Withdraw the needle (still needle up), then set the vial down. If you are using a second needle for the injection, swap needles now. Make sure the injection needle is securely fastened (usually a twist-on).
10. With the injection needle pointed up, tap the syringe and very slowly squeeze out the final bubbles. You might lose a bit of the solution, but it is important to be patient amount removing all of the significant bubbles (however, you need not worry about the suspended bubbles which are so tiny as to be nearly invisible).
11. If you need to change position to make the injection, put the protective cover on over the needle so you can set it down. Some people find it easiest to stand; others prefer to lay on their stomach if the buttock is target. If possible, have someone you trust make the actual injection; it is much easier that way.
12. Uncover the needle, grasp the outside of the syringe firmly (finger off the plunger), place the needle against your skin, perpendicular, then bravely push to a depth of roughly 2 1/2 - 3 1/2 cm , (1 - 1 1/3 inches). There should not be much pain past the initial prick. Once the needle is in, try not to shift your weight around or flinch such that the muscles there would move.
13. Still holding the outside of the syringe, pull back the plunger to be sure you did not hit a significant blood vessel. If you see no blood in the syringe, then very slowly but firmly depress the plunger. If you do see blood, then withdraw the needle, apply pressure to the site for a minute, then [optionally install a new needle and] try again a few centimeters away, or on the opposite side of your body.
14. Remove the needle from your body, replace the protective cover, and dispose of that part into a sharps container, or at least a container of strong composition that cannot be punctured by the used needles.
15. It is normal for there to be slight oozing of blood and/or oil from the injection site (and a small bruise later), given the large needle guage. If it oozes for more than a few seconds, apply pressure for a minute. If you are the extraordinarily tidy type, you can also place a dot bandaid over it, but it is not really necessary.

Congratulations!

How Can the Intended Effects of Hormone Therapy Be Maximized and the Dangers Minimized?

• Before starting hormone therapy, take a full physical exam, and have blood drawn to check liver function (enzymes). If you can possibly afford it, also take tests for clotting factors, thyroid, kidney, electrolyte, lipid (cholesterol), prolactin, sugar, estrogen, and androgen levels. It is also interesting to monitor the skeletal health via the calcium and phosphorus levels, especially if you are more than 40 years old.
• Repeat the liver test a few months after each significant increase of androgen dosage. At the very minimum, recheck it 6 months and 12 months after starting. Even after achieving a stable long-term (> 2yr) regimen, it is not a bad idea to recheck liver health again every couple of years.
• Be constantly aware of your body so that adjustments can be made if any new problems develop during therapy.
• Have regular medical checkups (minimally every year; more often if you have any significant health problem); pay close attention to vital signs.
• Eat well, and take a good multi-vitamin/mineral supplement to help be sure the body has everything it needs for new development. Also, milk thistle has been promoted as a liver tonic, which seems reasonable because it contains silymarin. Silymarin has been shown to protect the liver from free radical damage by directly acting as an antioxidant, as well as by increasing the liver's content of glutathione and superoxide dismutase, which help the liver detoxify a wide range of hormones, drugs, and chemicals. Perhaps most interesting is silymarin's reputed ability to stimulate protein synthesis and the production of new liver cells, suggesting that it may be useful not only in preventing acute liver toxicity, but also in promoting recovery from chronic liver damage.
• Do not start taking the maximum planned dosage of all hormones at once. Start with a low dosage of one, and carefully watch for negative vital signs and symptoms. If there are no problems after 2 months, increase the dosage to the planned level. Wait another 2 months before adding the next hormone or anti-hormone. Do not change the regimen radically or more often than once per 2 months. Give the body time to adjust.
• Use the lowest hormone dosage that affords the desired changes. Not everyone needs the same dosage, because of differences in body weight and genetically-disposed sensitivity to the hormones. Hormone dosage can usually be reduced to a nominal maintenance level after the ovaries are surgically removed. It is not recommended to take pre-operative dosages of hormones for more than about 3 years.
• Keep your hormone levels as even as you can. If possible, divide oral drugs into twice-daily portions. For injections, if you can stand the hassle and extra cost of syringes, divide your dose for taking every 1-2 weeks rather than letting it go 3-4 weeks.
• There might be an increased risk of arterial hardening (particularly in the heart) due to increased serum cholesterol levels. Change the diet to reduce cholesterol.
• Androgens can, in rare cases, stimulate various kinds of liver tumors and cysts, especially if the liver is already weakened by alcohol, drug use, or infection. Reduce alcohol and other drug intake. Monitor liver stress with a liver profile blood test every 6 months.
• If the menstrual cycle has not ceased within about 5 months of a steady androgen regimen, take a blood test to check the serum androgen level.
• Some recent studies seem to show that tobacco or marijuana smoking reduces the efficiency of androgen uptake.
• Even if most of the breast tissue is removed by a masectomy, there is enough tissue left to place female-to-male transsexuals at approximately the same risk for breast cancer as genetic males. Perform regular breast self-exams; have any unusual lumps checked immediately.

Results

A hormone therapy regimen that works well for one person may not for another. If development is not well under way in, say, 6 months, some experimentation may be in order; try different hormone types and/or combinations. However, if you change the regimen very often, it will be difficult to tell which one was working best. Be patient. The obvious exception is if you have a strong adverse effect that you or your physician deem dangerous; in that case you obviously must stop taking the hormone (or anti-hormone) in question. It is unusual for the therapy to not work; the most common cause is the choice of oral preparations since the absorbtion varies among individuals.

Hormone dosage can usually be reduced to a nominal maintenance level after the ovaries are surgically removed.

How Can One Obtain Hormones?

In the U.S., most reputable therapists and medical doctors who regularly work with transsexuals follow the Harry Benjamin Standards of Care, a plan that specifies that one should undergo a minimum of 3 months of psychotherapy to obtain a letter of recommendation to an endocrinologist. One can choose to work with doctors who do not follow the Benjamin Standards, but, in any case, it is a very good idea to meditate and cogitate on the implications for at least 3 months before starting hormone therapy. Some transsexuals find the Benjamin Standards too restrictive--even insulting; others find it worth the trouble to go through the hoop in order to be referred to an endocrinologist who is particularly knowledgeable in the treatment of transsexuals. Choose carefully.

One should only take hormones that were obtained directly from a licensed pharmaceutical distributor; the quality of drugs obtained through other channels is not only suspect, but likely dangerous--especially those in injectable form.

It is possible to have a health insurance company to cover hormones just like any other prescription drugs, especially if the doctor prescribes them for a "hormone imbalance" or "hormone replacement" rather than "transsexual hormone therapy." When a health insurance company subcontracts out prescription drug coverage to another company, benefits for hormones are not generally questioned since there is little communication between the two companies.

Some people in the U.S. have reportedly taken advantage of the U.S. FDA Personal Use Import Policy to purchase hormones directly from international sources. Please note that Confluence Publications does not have any further information about these potential sources.

Exactly what hormones are available? What Are the Details On Popularity, Dosage, Availability, Contraindications, Adverse Effects, Etc.?

Androgens

The following androgens are popular for treatment of female-to-male transsexuals, and are presented in descending order of preference in the humble opinion of the author:

Table 3: Popular androgens

Name	Safety and Efficacy
Testosterone Cypionate	Good
Testosterone Enanthate	Good
Testosterone	Good
Methyl Testosterone	Fair
Fluoxymesterone	Fair

Testosterone Cypionate

Brand Name Manufacturers	Depo-Testosterone by Pharmacia/Upjohn
Generic Manufacturers	Geneva Goldline Depotest by Hyrex Rugby Schein Star Steris URL Virilon IM by Star
Pharmacology	Apparently same as endogenous androgens
Delivery	100, 200mg/ml sustained-release intramuscular injection
Typical dosage	Pre-op 200-400mg/2-4wks Post-op 50-200mg/2-4wks
Availability	Approved by U.S. FDA. Schedule III controlled substance.
Indications	Breast cancer in females. Hormone replacement therapy in males.
Contraindications	Hypersensitivity to any component of the product. Kidney disease. Known or suspected breast cancer.
Adverse reactions	CNS Anxiety. Depression. Headache. Prickling or tingling skin. Gastrointestinal Cholestatic jaundice. Liver tumors and other liver disease. Nausea. Skin Acne. Male pattern baldness. Other Extreme allergic reaction. Increased serum cholesterol. Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Suppression of blood clotting factors.
Comments

Testosterone Enanthate

Brand Name Manufacturers	Delatestryl by Bio-Technology
Generic Manufacturers	Andro by Forest Delatest by Dunhall Everone by Hyrex Geneva Rugby Schein Steris URL
Pharmacology	Apparently same as endogenous androgens
Delivery	100, 200mg/ml sustained-release intramuscular injection
Typical dosage	Pre-op 200-400mg/2wks Post-op 50-200mg/2wks
Availability	Approved by U.S. FDA. Schedule III controlled substance.
Indications	Breast cancer in females. Hormone replacement therapy in males.
Contraindications	Hypersensitivity to any component of the product. Kidney disease. Known or suspected breast cancer.
Adverse reactions	CNS Anxiety. Depression. Headache. Prickling or tingling skin. Gastrointestinal Cholestatic jaundice. Liver tumors and other liver disease. Nausea. Skin Acne. Male pattern baldness. Other Extreme allergic reaction. Increased serum cholesterol. Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Suppression of blood clotting factors.
Comments	The author sees nothing in the PDR that would make this drug inferior to testosterone cypionate, but the cypionate seems to be more popular.

Testosterone

Brand Name Manufacturers	Androderm by SK Beecham Testoderm by Alza
Generic Manufacturers
Pharmacology	Apparently same as endogenous androgens
Delivery	2.5, 4, 6mg/day transdermal film, preferrably on scrotal/surgery area
Typical dosage	Pre-op ? Post-op 4-6mg/day (1 film changed daily)
Availability	Approved by U.S. FDA. Schedule III controlled substance.
Indications	Hormone replacement therapy in males.
Contraindications	Hypersensitivity to any component of the product.
Adverse reactions	CNS Anxiety. Depression. Headache. Prickling or tingling skin. Gastrointestinal Cholestatic jaundice. Liver tumors and other liver disease. Nausea. Skin Acne. Oily skin. Male pattern baldness. Other Extreme allergic reaction. Increased serum cholesterol. Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Suppression of blood clotting factors.
Comments

Methyl Testosterone

Brand Name Manufacturers	Testred by ICN
Generic Manufacturers	Virilon by Star Global
Pharmacology	Synthetic testosterone
Delivery	10mg oral capsules 10, 25mg oral tablets
Typical dosage	Pre-op ? Post-op 10-50mg/day
Availability	Approved by U.S. FDA. Schedule III controlled substance.
Indications	Breast cancer in females. Hormone replacement therapy in males.
Contraindications	Hypersensitivity to any component of the product. Kidney disease. Known or suspected breast cancer.
Adverse reactions	CNS Anxiety. Depression. Headache. Prickling or tingling skin. Gastrointestinal Cholestatic jaundice. Liver tumors and other liver disease. Nausea. Skin Acne. Male pattern baldness. Other Extreme allergic reaction. Increased serum cholesterol. Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Suppression of blood clotting factors.
Comments

Fluoxymesterone

Brand Name Manufacturers	Halotestin by Upjohn
Generic Manufacturers	Major Qualitest Rosemont Rugby URL
Pharmacology	Apparently similar to endogenous testosterone
Delivery	2, 5, 10mg oral tablets
Typical dosage	Pre-op ? Post-op 5-20mg/day
Availability	Approved by U.S. FDA. Schedule III controlled substance.
Indications	Breast cancer in females. Hormone replacement therapy in males.
Contraindications	Hypersensitivity to any component of the product. Heart, liver, and kidney disease. Known breast cancer.
Adverse reactions	CNS Anxiety. Depression. Headache. Prickling or tingling skin. Eyes Gastrointestinal Cholestatic jaundice. Liver tumors and other liver disease. Nausea. Skin Acne. Male pattern baldness. Oily skin. Other Mild to extreme allergic reaction. Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Suppression of blood clotting factors.
Comments

Other prescription androgenic hormones are available, but because they have dangerous adverse effects and their primary indication is not for male hormone replacement, they are not listed here. Specifically, anabolic steroids should be eschewed in favor of the androgens listed above.

The following natural sources of phytoandrogens (androgen-like compounds) have been identified, but the author is not aware of an effective course of treatment using them. Since phytoandrogens are not nearly as efficacious as true androgens, huge and potentially toxic amounts of these items would have to be consumed. They are presented in alphabetical order: Diosterol, Gamma Oryzanol, Mesobolin, Sarsparilla (Smilax Officinalis).

Anti-Estrogens

The following anti-estrogens have been suggested for treatment of treatment of pre-operative female-to-male transsexuals, and are presented in descending order of preference in the humble opinion of the author:

Table 4: Anti-estrogens

Name	Safety and Efficacy
Danazol	Good
Tamoxifen Citrate	Fair

Danazol

Brand Name Manufacturers	Danacrine by Sanofi Winthrop
Generic Manufacturers	Barr Warner Chilcott
Pharmacology	FSH and LH production inhibitor. Estrogen receptor antagonist. Weak androgen.
Delivery	50, 100, 200mg oral capsules
Typical dosage	Pre-op 200-400mg/day
Availability	Approved by U.S. FDA
Indications	Endometriosis. Estrogen dependent fibrocystic breast disease. Hereditary engorgement of blood vessels in males and females.
Contraindications	Hypersensitivity to light. Markedly impaired liver, kidney, or heart function.
Adverse reactions	Gastrointestinal Cholestatic jaundice. Skin Acne. Oily skin. Flushing. Sweating. Vaginal dryness. Other Blood clotting disorders. Fluid retention. Increase of cholesterol in blood. Increase of fluid pressure in skull. Liver peliosis and benign tumors.
Comments

Tamoxifen Citrate

Brand Name Manufacturers	Nolvadex by Zeneca
Generic Manufacturers	Barr Quality Care
Pharmacology	Nonsteroidal estrogen receptor antagonist
Delivery	10, 20mg oral tablets
Typical dosage	Pre-op 20-40mg/day
Availability	Approved by U.S. FDA
Indications	Breast cancer
Contraindications	Known sensitivity to any component of the product
Adverse reactions	CNS Dizziness. Headache. Mental depression. Eyes Cataracts. Corneal changes. Gastrointestinal Cholestatic jaundice. Distaste for food. Nausea. Vomiting. Skin Scalp hair loss. Vaginal itchiness. Other Bone pain. Decreased leukocyte blood count. Decreased platelet blood count. Fluid retention. Hot flashes. Increased calcium level in blood. Kidney dysfunction. Liver dysfunction.
Comments

Prescription adrenal estrogen production inhibitors are available but not listed because adrenal estrogen production is insignificant (i.e., about the same as in males) in comparison to gonadal estrogen production. Adrenal estrogens are best ignored, or if absolutely necessary, countered with a mild estrogen receptor antagonist.

Other Anti-Hormones (GnRH Agonists)

These pharmaceuticals can be used to dramatically reduce gonadal hormone production in both males and females. They are used mainly by pediatricians to reduce precocious puberty, so it might be difficult to persuade a doctor to prescribe them for an adult. Also, they are very expensive. None the less, this type of chemical castration is worth investigating for those cases when the pre-operative female-to-male cannot take the hormones of choice because of other health problems (e.g., hormone dependent tumors or blood clotting disorders), and cannot yet have the surgery performed (note that such a problem is quite rare). They are presented in descending order of preference in the humble opinion of the author:

Table 5: Anti-hormones

Name	Safety and Efficacy
Goserelin Acetate	Excellent
Nafarelin Acetate	Excellent
Leuprolide Acetate	Fair

Goserelin Acetate

Brand Name Manufacturers	Zoladex by Zeneca
Generic Manufacturers	None
Pharmacology	GnRH agonist. After an initial stimulating phase, the pituitary is desensitized to GnRH, which causes it to stop producing LH, which in turn dramatically decreases gonadal production of hormones within a month.
Delivery	Sustained release subcutaneous injection 3.6, 10.8mg
Typical dosage	Pre-op 3.6mg/month (3.6mg implant is for 1 month; 10.8 mg implant is for 3 months)
Availability	Approved by U.S. FDA
Indications	Androgen-sensitive prostate cancer
Contraindications	Known hypersensitivity to GnRH, GnRH analogues, or any of the components of the product
Adverse reactions	CNS Dizziness. Insomnia. Lethargy. Gastrointestinal Anorexia. Nausea. Skin Sweating. Other Congestive heart failure. Fluid retention. Hot flashes. Increased calcium level in blood. Mild to severe allergic reactions. Obstructive pulmonary disease. Ureteral and spinal compression.
Comments

Nafarelin Acetate

Brand Name Manufacturers	Synarel by Searle
Generic Manufacturers	None
Pharmacology	GnRH agonist. After an initial stimulating phase, The pituitary is desensitized to GnRH, which causes it to stop producing LH, which in turn dramatically decreases gonadal production of hormones within one month.
Delivery	Nasal spray
Typical dosage	Pre-op 1600mcg/day (2 sprays into each nostril twice a day)
Availability	Approved by U.S. FDA
Indications	Central precocious puberty. Endometriosis.
Contraindications	Hypersensitivity to GnRH, GnRH agonists analogs or any component of the product
Adverse reactions	CNS Headache. Insomnia. Mental depression. Skin Acne. Body odor. Increase of body and facial hair. Itchiness. Itchy, fluid-filled patches of skin. Oily skin. Rash. Vaginal dryness. Other Chest pain. Fluid retention. Hot flashes. Muscle pain. Nasal irritation. Ovarian cysts. Shortness of breath. Vaginal bleeding.
Comments

Leuprolide Acetate

Brand Name Manufacturers	Lupron by Tap
Generic Manufacturers	None company
Pharmacology	GnRH agonist. After an initial stimulating phase, the pituitary is desensitized to GnRH, which causes it to stop producing LH, which in turn dramatically decreases gonadal production of hormones within one month.
Delivery	5, 7.5, 11.25, 15, 22.5mg sustained-release intramuscular injection
Typical dosage	Pre-op 3.75-7.5mg/month
Availability	Approved by U.S. FDA
Indications	Advanced prostate cancer. Endometriosis.
Contraindications	Hypersensitivity to GnRH or GnRH analogs.
Adverse reactions	CNS Anxiety. Delusions. Dizziness. Headache. Hearing disorders. Insomnia. Memory disorder. Nerve disorders. Personality disorder. Eyes Eye disorders. Gastrointestinal Anorexia. Constipation. Coughing up blood. Dry mouth. Nausea. Thirst. Vomiting. Skin Change of facial and body hair. Skin rash. Other Ankylosing spondylosis. Blood in the urine. Bone and muscle pain. Change in heart electrical activity. Congestive heart failure. Decrease of bone density. Decreased tolerance of protein. Decreased red blood cell count. Decreased white blood cell count. Difficulty urinating. Elevated blood pressure. Elevated LDH. Elevated phosphorus. Escape of blood into the tissues from ruptured blood vessels. Fluid retention. Hair loss. Hot flashes. Increased heart beat rate. Increased uric acid. Increased urination frequency or urgency. Lactation. Liver disorder. Loss of strength. Low blood pressure. Lymphadenopathy. Mild to extreme allergic reaction. Palpitations. Pelvic fibrosis. Penile swelling. Prostate pain. Pulmonary disorders. Respiratory disorders. Temporary increase of hormone production. Temporary suspension of respiration and circulation.
Comments

Where is there more information about hormones?

• Articles
• Books
• Web Sites

Medline Articles

These are the articles in Medline containing the words "transsexual" and "hormone" and less than 10 years old, as of 1998 May, courtesy of the U.S. National Institute of Health.

35 citations found

Other Formats:
Links:

Order this document

Arch Sex Behav 1998 Apr;27(2):209-226

Endocrine therapy of transsexualism and potential complications of long-term treatment.

Futterweit W

Division of Endocrinology, Mount Sinai School of Medicine, New York, New York 10029, USA.

[Medline record in process]

Physiological principles of the interrelationship of sex hormones and their regulation are the foundation of understanding appropriate treatment of the transsexual patient. While both genetic males and females have estrogens and androgens, the quantitative sex hormone production is genetically predetermined by sex hormone production both in the gonads and via peripheral conversion of hormone precursors to sex steroids. Sex hormones exert a negative feedback on the hypothalamus and pituitary gland whereby gonadotropin-releasing hormone (GnRH), pituitary luteinizing hormone (LH), and follicle-stimulating hormone (FSH) are regulated or suppressed by the endogenous levels of these hormones. Sex hormonal therapy induces attenuated GnRH stimulation of LH and FSH causing a reduction of serum sex hormone levels. It is clear that estrogen as well as androgen therapy have a dual role: (i) inducti on of feminization or virilization and (ii) suppression of the hypothalamic-pituitary-gonadal axis leading to a reduction of endogenous estradiol or testosterone secretion. Cross-sex hormonal treatment may have substantial medical side effects. The smallest dosage of hormonal therapy compatible with the above clinical aims should be used.

PMID: 9562902, UI: 98223997

---

Other Formats:
Links:

Order this document

J Clin Endocrinol Metab 1998 Feb;83(2):550-553

Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females.

Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD

Department of Endocrinology, Division of Andrology, Hospital Vrije Universiteit, Amsterdam, The Netherlands.

Plasma total homocysteine (tHcy) levels are higher in men vs. premenopausal women, but it is not known whether this difference is related to sex steroids. The effects of cross-sex hormone administration on plasma tHcy levels were therefore investigated. Plasma tHcy levels were measured at baseline and after 4 months of treatment in 17 male-to-female (M-->F) transsexuals treated with ethinyl estradiol (100 micrograms/day), in combination with the antiandrogen, cyproterone acetate (100 mg/day), and in 17 female-to-male (F-->M) transsexuals treated with testosterone esters (250 mg/2 weeks, im). In M-->F transsexuals, the plasma tHcy level decreased from geometric mean 8.2 mumol/L to 5.7 mumol/L (P < 0.001); and in F-->M transsexuals, it increased from 7 .7 mumol/L to 9.0 mumol/L (P = 0.005). In M-->F transsexuals, changes in serum sex hormone-binding globulin levels correlated negatively, and changes in plasma creatinine and albumin levels correlated positively, with changes in plasma tHcy levels. In F-->M transsexuals, changes in serum 17 beta-estradiol levels correlated negatively, and changes in plasma creatinine levels correlated positively, with changes in plasma tHcy levels. We conclude that tHcy levels decrease after estrogen + antiandrogen administration to male (transsexual) subjects, and levels increase after androgen administration to female (transsexual) subjects. These changes may be both primary and secondary to the anabolic/catabolic effects, as reflected by changes of creatinine and albumin levels after cross-sex hormone administration.

PMID: 9467573, UI: 98128702

---

Other Formats:
Links:

Order this document

Arch Sex Behav 1997 Dec;26(6):589-605

Transvestism: a survey of 1032 cross-dressers.

Docter RF, Prince V

Department of Psychology, California State University, Northridge 91330-8255, USA.

One thousand and thirty-two male periodic cross-dressers (transvestites) responded to an anonymous survey patterned after Prince and Bentler's (1972) report. With few exceptions, the findings are closely related to the 1972 survey results. Eighty-seven percent described themselves as heterosexual. All except 17% had married and 60% were married at the time of this survey. Topics surveyed included demographic, childhood, and family variables, sexual orientation and sexual behavior, cross-gender identity, cross-gender role behavior, future plans to live entirely as a woman, and utilization of counseling or mental health services. Of the present sample, 45% reported seeking counseling compared to 24% of the 1972 survey, and those reporting strong transsexual inclinations were up by 5%. Today's transvestites strongly prefer both their masculine and fem inine selves equally. A second research objective was to identify variables discriminating between so-called Nuclear (stable, periodic cross-dressers) and Marginal transvestites (more transgendered or transsexually inclined); 10 strongly discriminating parameters were found. The most important are (i) cross-gender identity, (ii) commitment to live entirely as a woman, (iii) taking steps toward body feminization, (iv) low sexual arousal to cross-dressing. Neither age nor experience as a cross-dresser were found to be correlates of cross-gender identity. Although the present generation of transvestites describe themselves much as did similar subjects 20 years ago, the percentage migrating toward full-time living as a woman is greater.

PMID: 9415796, UI: 98077637

---

Other Formats:
Links:

Order this document

Clin Endocrinol (Oxf) 1997 Sep;47(3):337-342

Mortality and morbidity in transsexual subjects treated with cross-sex hormones.

van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ

Department of Andrology, Free University Hospital, Amsterdam, The Netherlands.

OBJECTIVE: The optimum steroid hormone treatment regimes for transsexual subjects has not yet been established. We have investigated the mortality and morbidity figures in a large group of transsexual subjects receiving cross-sex hormone treatment. DESIGN: A retrospective, descriptive study in a university teaching hospital. SUBJECTS: Eight hundred and sixteen male-to-female (M-->F) and 293 female-to-male (F-->M) transsexuals. INTERVENTIONS: Subjects had been treated with cross-sex hormones for a total of 10,152 patient-years. OUTCOME MEASURES: Standardized mortality and incidence ratios were calculated from the general Dutch population (age- and gender-adjusted) and were also compared to side effects of cross-sex hormones in transsexuals reported in the literature. RESULTS: In both the M-->F and F-- 2;M transsexuals, total mortality was not higher than in the general population and, largely, the observed mortality could not be related to hormone treatment. Venous thromboembolism was the major complication in M-->F transsexuals treated with oral oestrogens and anti-androgens, but fewer cases were observed since the introduction of transdermal oestradiol in the treatment of transsexuals over 40 years of age. No cases of breast carcinoma but one case of prostatic carcinoma were encountered in our population. No serious morbidity was observed which could be related to androgen treatment in the F-->M transsexuals. CONCLUSION: Mortality in male-to-female and female-to-male transsexuals is not increased during cross-sex hormone treatment. Transdermal oestradiol administration is recommended in male-to-female transsexuals, particularly in the population over 40 years in whom a high incide nce of venous thromboembolism was observed with oral oestrogens. It seems that in view of the deep psychological needs of transsexuals to undergo sex reassignment, our treatment schedule of cross-sex hormone administration is acceptably safe.

PMID: 9373456, UI: 98040787

---

Other Formats:
Links:

Order this document

Arch Sex Behav 1997 Apr;26(2):143-157

Anthropometrical measurements and androgen levels in males, females, and hormonally untreated female-to-male transsexuals.

Bosinski HA, Schroder I, Peter M, Arndt R, Wille R, Sippell WG

Department of Sexual Medicine, Medical School, Christian Albrechts University Keil, Germany.

To elucidate the relationship between body build, androgens, and transsexual gender identity, anthropometric measurements were assessed in 15 hormonally untreated female-to-male-transsexuals (FMT). Nineteen healthy women (CF) (X = 22 years; 2 months), and 21 healthy men (CM) (X = 23; 7) were enrolled as controls. Baseline levels of testosterone (T; ng/dl), androstenedione (A4; ng/dl), dehydroepiandrosterone sulfate (DHEAS; ng/ml), and sex-hormone binding globulin (SHBG; microgram/ml) were assessed in 12 FMT, 15 CF, and in all CM. No control was under hormonal medication (including contraceptives). Absolute measurements in FMT were in accordance with their biological sex: they showed only small differences from the CF. However, FMT differed from CF in 7 of 14 sex-dimorphic indices of masculinity/femininity in body build. Of these 14 indices, 9 did not show a difference between FMT and CM. Hence, FMT presented a more masculine body build, particularly in fat distribution and bone proportions. Levels of T and A4 were significantly higher in FMT than in CF (T: 54.0 +/- 13.8 vs. 41.1 +/- 12.8; A4: 244.8 +/- 73.0 vs. 190.5 +/- 49.3), while DHEAS was higher in CM (3335 +/- 951) than in CF (2333 +/- 793) and in FMT (2679 +/- 1089). Altogether, 83.3% of FMT and 33.3% of CF were above normal values for at least one measured androgen. SHBG in FMT (1.21 +/- 0.70) and CF (1.87 +/- 0.91) was higher than in CM  0;0.49 +/- 0.18) and tended to be higher in CF than in FMT. Unbound T (T/SHBG ratio) was higher in FMT (72.0 +/- 67.6) than in CF (26.4 +/- 15.1) and correlated positively with manly body shape. Findings are discussed in relation to etiology of transsexualism.

PMID: 9101031, UI: 97255684

---

Other Formats:
Links:

Order this document

J Am Acad Child Adolesc Psychiatry 1997 Feb;36(2):263-271

Sex reassignment of adolescent transsexuals: a follow-up study.

Cohen-Kettenis PT, van Goozen SH

Department of Child and Adolescent Psychiatry, Rudolph Magnus Institute of Neurosciences, Utrecht, The Netherlands.

OBJECTIVE: To investigate postoperative functioning of the first 22 consecutive adolescent transsexual patients of our gender clinic who underwent sex reassignment surgery. METHOD: The subjects were interviewed by an independent psychologist and filled out a test battery containing questionnaires on their psychological, social, and sexual functioning. All subjects had undergone surgery no less than 1 year before the study took place. Twelve subjects had started hormone treatment between 16 and 18 years of age. The posttreatment data of each patient were compared with his or her own pretreatment data. RESULTS: Postoperatively the group was no longer gender-dysphoric; they scored in the normal range with respect to a number of different psychological measures and they were socially functioning quite well. Not a single subject expressed feelings of regret concerning the decision to undergo sex reassignment. CONCLUSIONS: Starting the s ex reassignment procedure before adulthood results in favorable postoperative functioning, provided that careful diagnosis takes place in a specialized gender team and that the criteria for starting the procedure early are stringent.

PMID: 9031580, UI: 97183473

---

Other Formats:
Links:

Order this document

Contracept Fertil Sex 1996 Nov;24(11):834-846

[Role of hormones in sexual dysfunctions, homosexuality, transsexualism and deviant sexual behavior: diagnostic and therapeutic consequences].

[Article in French]

Buvat J, Lemaire A, Ratajczyk J

Association pour l'etude de la pathologie de l'appareil reproducteur et de la psychosomatique (EPARP), Lille.

Hormones only play a minor role in sexual dysfunctions. They are clearly involved only in erectile dysfunction. Total testosterone is low in 8% of those patients, but only 32% of them are improved with androgen therapy. Free testosterone is also electively decreased in 30% and bioavailable (non SHBG bound) testosterone in 15%. However androgen-therapy is still less effective in these subgroups. Plain hyperprolactinemia is found in only 0,7% of the cases. Half of them result from a pituitary adenoma. The other endocrine dysfunctions are still scarcer. This data cannot justify a systematic determination of serum prolactin and testosterone in sexual dysfunctions. A cost effective hormonal screening is proposed, whereas the role of androgen-therapy in erectile dysfunction with or without hypogonadism is discussed. The hypothesis of an "inverted brain sexual differentiation" in homosexuality and for transsexualism, resulting from an abnormal antenatal endocrine milieu is reviewed. It cannot obviously explain by itself these conditions, but some amazing morphological findings in transsexual people do not permit to totally refute it. Lastly the role of androgens in paraphilia and parapaphilia related disorders seems limited to the arousal of an abnormal sexual behaviour previously scheduled by non hormonal mechanisms. However anti-androgens are in such cases one of the main effective treatment.

Publication Types:

• Review
• Review, tutorial

PMID: 8991588, UI: 97114880

---

Other Formats:
Links:

Order this document

Exp Clin Endocrinol Diabetes 1996;104(6):413-419

Multistep treatment concept of transsexual patients.

Schlatterer K, von Werder K, Stalla GK

Max-Planck-Institute of Psychiatry, Dept. Endocrinology, Munchen, Germany.

Here we present a pragmatic multistep approach for the treatment of transsexual patients. The importance of an individually designed cross-gender hormone replacement therapy embedded in a multidisciplinary treatment concept, provided by psychiatrists, endocrinologists and surgeons, is demonstrated. Following this concept outcome of therapy has been improved in the last years. Over the last 5 years we have gained substantial experience in the cross-gender hormone treatment of transsexual patients. By continuous follow-up examinations and therapy adjustment the risk of side effects accompanying this therapy has been significantly minimized. This report is designed as a guideline to the clinical endocrinologist for the handling and treatment of transsexual patients.

Publication Types:

• Review
• Review, tutorial

PMID: 9021341, UI: 97173435

---

Other Formats:
Links:

Order this document

Clin Endocrinol (Oxf) 1995 Oct;43(4):415-421

Effects of gonadal androgens and oestrogens on adrenal androgen levels.

Polderman KH, Gooren LJ, van der Veen EA

Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands.

OBJECTIVE: The physiological role of adrenal androgens in humans remains unclear. Furthermore, there are few data on the relation between sex steroids and adrenal androgen production. We have assessed the effects of sex steroid hormone administration on adrenal androgen levels, by studying a large group of transsexual patients. DESIGN: A non-randomized intervention. SETTING: A university teaching hospital. PATIENTS: Thirty-one male-to-female and 22 female-to-male transsexual patients. MEASUREMENTS: Plasma levels of adrenal androgens were measured in a group of male-to-female and female-to-male transsexual patients both before and during cross-gender hormone treatment. This treatment involves administration of testosterone esters to women and of ethinyloestradiol and cyproterone acetate to men. RESULTS: High dose sex steroid administration had marked effects on adrenal andr ogens levels, which decreased by 27-48% in males treated with ethinyloestradiol and increased by 23-70% in females treated with testosterone. CONCLUSION: We conclude that administration of high doses of testosterone and oestradiol exert opposing effects on adrenal androgen production.

Publication Types:

• Clinical trial

Comments:

• Comment in: Clin Endocrinol (Oxf) 1996 Apr;44(4):490-1

PMID: 7586614, UI: 96046830

---

Other Formats:
Links:

Order this document

Arch Androl 1995 Sep;35(2):127-133

Aromatization of [4-14C]testosterone to [14C]estradiol-17 beta by testicular tissue from male-to-female transsexuals on estrogen therapy.

Gunasegaram R, Loganath A, Peh KL, Ratnam SS

Institute of Science and Forensic Medicine, National Blood Centre, Singapore, Republic of Singapore.

Abnormality in testicular biosynthesis of sex hormones may accompany or cause transsexualism. With a view to determine whether the cells of male transsexual testicular tissue possess aromatic cytochrome P-450 activity, homogenates of the tissue from 4 phenotypic male-to-female transsexuals (2 Chinese and 2 Malays, aged 23-34 years) with XY karyotype who had been on estrogen therapy for 9-17 years until orchidectomy were incubated with [4-14C]testosterone as substrate. Using reverse-isotope dilution analysis, identity was established for [14C]estradiol-17 beta. No such metabolite was found in parallel incubations of heat-denatured enzymes. The extent of enzyme-catalyzed conversion was 9.3 x 10(-3) to 3.4 x 10(-2)%. The specific biosynthetic aromatase cytochrome P-450 activity contained in the tissue system can synthesize [14C]est radiol-17 beta from [4-14C]testosterone. Elevated aromatic expression in situ may have important effects on target tissues.

PMID: 8579473, UI: 96103792

---

Other Formats:
Links:

Order this document

Psyche (Stuttg) 1995 Sep;49(9-10):811-837

[Transsexual wish and and cis-sexual defense].

[Article in German]

Sigusch V

Klinikum, J.W. Goethe-Universitat, Abteilung fur Sexualwissenschaft, Frankfurt am Main.

The desire of trans-sexual patients to appropriate the physical attributes of the opposite sex via hormone treatment or surgery confronts psychoanalysis and sex research with problems that are not only psychological in nature. Sigusch uses the term "defence" here not only in a technical sense but also in an epistemological, discourse-analytic and disposition-analytic register. The general dispositions determining the reality of gender and gender difference are "cis-sexual" in nature. The polarity they display extends to the physical and manifests itself in the form of sexual binarism. The author coins the consciously neologistic term "cis-sexual" to describe individuals where physical gender and gender identity are completely and "naturally" co-extensive. Only the realization that "second-nature" is in reality primary can trigger the detotalization of so-called trans-sexuality that Sigusch is concerned to call into question.

Publication Types:

• Review
• Review, tutorial

PMID: 7480808, UI: 96068432

---

Other Formats:
Links:

Order this document

J Endocrinol Invest 1995 Jun;18(6):420-426

The effect of non-steroidal antiandrogen flutamide on luteinizing hormone pulsatile secretion in male-to-female transsexual subjects.

Giusti M, Falivene MR, Carraro A, Cuttica CM, Valenti S, Giordano G

Cattedra di Endocrinologia, University of Genova, Italy.

We evaluated LH pulsatile patterns before and 4 weeks after the oral administration of flutamide (750 mg/day) in 9 male-to-female transsexuals (age range 17-28 yr) requesting gender reassignment. Flutamide was given to explore the feedback role of androgens on the LHRH-LH unit in LH pulsatility in transsexuals. Seven normal age-matched men served as a control group, without receiving flutamide, due to ethical considerations. LH pulsatility was evaluated on samples collected every 15 min for 360 min. FSH, PRL, cortisol, SHBG and sex steroids were evaluated on pooled samples. LH pulses were analyzed by the Santen and Bardin algorithm, slightly modified. No differences in FSH, PRL, total- or free-testosterone, estradiol and SHBG levels were noted between transsexuals and controls. Normal circadian cortisol decline was observed in all subjects. Mean LH levels (p < 0.05) and LH pulses (p < 0.01) were significantly lower in transsexuals. Flutamide induced an increase in mean LH and testosterone levels (p < 0.01). After flutamide administration there was an increase in LH pulse frequency (P < 0.01) and the frequency and amplitude of LH pulses in transsexuals were restored to levels observed in controls. No differences in FSH, PRL or estradiol levels were found after flutamide. These data suggest that a decrease in LH pulse frequency could be an endocrine marker in male-to-female transsexuals. An increase in endogenous androgen negative feed-back could be speculated in these subjects. However, normal testosterone levels indirectly suggest that a normal that a normal qualitative LH secretion is maintained.

Publication Types:

• Clinical trial

PMID: 7594235, UI: 96037312

---

Other Formats:
Links:

Order this document

Int J Androl 1995 Apr;18(2):88-96

Quantification of androgen receptor and follicle-stimulating hormone receptor mRNA levels in human and monkey testes by a ribonuclease-protection assay.

Dankbar B, Sohn M, Nieschlag E, Gromoll J

Institute of Reproductive Medicine, University of Munster, Germany.

A sensitive, solution-hybridization ribonuclease-protection assay (RPA) was established to quantify the expression of mRNA for the androgen receptor (AR) and follicle-stimulating hormone receptor (FSHR) in total RNA samples isolated from tissues of the cynomolgous monkey, human testes obtained from elderly patients undergoing orchidectomy because of prostatic carcinoma or from transsexual men undergoing gender reassignment as well as human cell lines DU 145, REP and RVP. Sensitivity experiments revealed that, in the human and monkey, 1-2 micrograms of total RNA were sufficient to achieve quantifiable signals of the different receptor mRNA species. Quantification of AR and FSHR mRNA levels showed a 1.7-fold higher expression of AR mRNA and a 2.4-fold higher expression of FSHR mRNA in the monkey testes compared to human testes from patients with prostatic carcinoma. Normal spermatogenesis in both hu man and monkey testes indicated no relationship between spermatogenic status and receptor expression. The significantly lower expression of AR and FSHR mRNA in humans than in monkeys might therefore be either age- or species-related. Quantification of mRNA for AR and FSHR in the testis of the transsexual patients undergoing oestrogen and antiandrogen treatment displayed a drastic increase (4.5-fold) in mRNA for the AR, whereas mRNA for the FSHR was barely detectable. Due to its high sensitivity, reproducibility and its ability to quantify mRNA transcripts, the RPA is a useful tool for investigating expression of low abundant receptor genes and their regulation when only very small amounts of tissue are available. Furthermore, it is suitable for use in clinical and experimental studies in which accurate quantification of transcripts is necessary.

PMID: 7665215, UI: 95394504

---

Other Formats:
Links:

Order this document

Prog Growth Factor Res 1995;6(2-4):397-408

Circulating and ovarian IGF binding proteins: potential roles in normo-ovulatory cycles and in polycystic ovarian syndrome.

Giudice LC, van Dessel HJ, Cataldo NA, Chandrasekher YA, Yap OW, Fauser BC

Department of Gynecology and Obstetrics, Stanford University Medical Center, CA 94305, USA.

IGFs function as co-gonadotropins in the ovary, facilitating steroidogenesis and follicle growth. IGFBP-1 to -5 are expressed in human ovary and mostly inhibit IGF action in in vitro ovarian cell culture systems. In the clinical disorder of polycystic ovarian syndrome (PCOS), which is characterized by hyperandrogenemia, polycystic ovaries and anovulation, follicles have a higher androgen: estradiol (A : E2) content and growth is arrested at the small antral stage. In the PCOS follicle, follicle stimulating hormone (FSH) and IGF levels are in the physiologic range, and even in the face of abundant androstenedione (AD) substrate, aromatase activity and E2 production are low. When PCOS granulosa are removed from their ovarian environment, they respond normally or hyperrespond to FSH. It has been postulated that an inhibitor of IGF's synergistic actions with FSH on aromatase a ctivity may be one (or more) of the IGFBPs, which contributes to the arrested state of follicular development commonly observed in this disorder. High levels of IGFBP-2 and IGFBP-4 are present in follicular fluid (FF) from androgen-dominant follicles (FFa) from normally cycling women and in women with PCOS. This is in marked contrast to the near absence of these IGFBPs in estrogen-dominant FF (FFe), determined by Western ligand blotting. Regulation of granulosa-derived IGFBPs is effected by gonadotropins and insulin-like peptides. In addition, an IGFBP-4 metallo-serine protease is present in FFe, but not in FFa in ovaries from normally cycling women and those with PCOS, although the IGFBP-4 protease is present in PCOS follicles hyperstimulated for in vitro fertilization. Recent studies demonstrate that IGF-II in FFe is higher than in FFa' whereas IGF-I, IG FBP-3 and IGFBP-1 levels do not differ, underscoring the importance of local IGF-II production by the granulosa and the importance of IGFBP-4 and IGFBP-2 in regulation of IGF-II action within the follicle during its developmental pathway as an E2- or A-dominant follicle. In the androgen-treated female-to-male transsexual (TSX) model for PCOS, IGF-I, IGF-II, IGFBP-3 and IGFBP-1 levels do not differ.

Publication Types:

• Review
• Review, tutorial

PMID: 8817683, UI: 96414662

---

Other Formats:
Links:

Order this document

Hum Pathol 1994 Nov;25(11):1198-1204

Androgen receptor expression in human ovarian and uterine tissue of long-term androgen-treated transsexual women.

Chadha S, Pache TD, Huikeshoven JM, Brinkmann AO, van der Kwast TH

Department of Pathology, Erasmus University Rotterdam, The Netherlands.

Androgen receptor (AR) modulation in human uteri and ovaries of long term androgen-treated transsexual female patients was investigated. Androgen receptor expression was evaluated immunohistochemically in the ovaries of 11 and the endometria and myometria of six androgen-treated transsexual female patients. This was compared with AR expression in the ovaries and uteri of premenopausal and postmenopausal women not receiving treatment and in 10 ovaries of female patients with polycystic ovarian disease (PCOD). In the normal ovaries germinal epithelium, granulosa cells of antral follicles, corpus luteum, and thecal and stromal cells exhibited moderate AR expression. The more intense and uniform staining of ovarian stroma of female transsexual patients and those of patients with PCOD compared with ovarian stroma of normal controls was most remarkable. This similarity in histology and distribution of ARs supports the hypothesis that PCOD is an androgen-mediated disorder. Immunostaining for ARs was only occasionally detectable in the uteri of premenopausal and postmenopausal women. In contrast, myometrial and endometrial stroma of the uteri of female transsexual patients displayed an intense and diffuse nuclear immunostaining, but glandular epithelia remained unstained. Western blot analysis of the ovaries and uterine myometrial tissue samples from transsexual female patients confirmed the presence of the 110-kd AR molecule. Because the androgen treatment of some transsexual female patients was discontinued 6 weeks before they underwent hysterosalpingo-oophorectomy, our data indicate a stable and persistent androgen-induced up-regulation of AR expression in ovaries.

PMID: 7959665, UI: 95048264

---

Other Formats:
Links:

Order this document

Arch Pathol Lab Med 1994 May;118(5):562-565

Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study.

Kovacs K, Stefaneanu L, Ezzat S, Smyth HS

Department of Pathology, St Michael's Hospital, Toronto, Ontario, Canada.

Pituitary adenoma developed in a 33-year-old male-to-female transsexual patient who was given estrogen, starting at 16 years of age; the pituitary adenoma was surgically removed and studied by light microscopy, immunocytochemistry, and in situ hybridization. The adenoma cells were immunoreactive for prolactin, and exhibited a strong signal for prolactin and estrogen receptor messenger RNAs and a weak signal for dopamine receptor messenger RNA. The question of whether the development of an adenoma was incidental or was the direct effect of estrogen or whether it was mediated via other mechanisms, such as activation of growth factors or oncogenes or inhibition of tumor-suppressing genes or other genetic abnormalities, remained unresolved. The present case, which, to our knowledge, is the first to describe structural findings of a pituitary adenoma in a transsexual patient who was given estrogen, reinforces the vie w that protracted stimulation may play a role in the genesis of endocrine tumors.

PMID: 8192565, UI: 94250127

---

Other Formats:
Links:

Order this document

Clin Endocrinol (Oxf) 1994 May;40(5):595-601

Testosterone administration increases adrenal response to adrenocorticotrophin.

Polderman KH, Gooren LJ, van der Veen EA

Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands.

OBJECTIVE: Various studies have demonstrated coexistence of ovarian and adrenal hyperandrogenism in women. This study was designed to determine whether testosterone can increase the response of the adrenal gland to stimulation by adrenocorticotrophin (ACTH). DESIGN: Non-randomized intervention in a university teaching hospital. PATIENTS: Twenty androgen-treated female-to-male transsexual patients (10 ovariectomized and 10 non-ovariectomized) and 10 normal female controls. MEASUREMENTS: ACTH stimulation tests were performed in all subjects. Baseline values and the increase above baseline values after ACTH stimulation were assessed for cortisol and the adrenal androgens androstenedione, dehydroepiandrosterone and dehydroepiandrosterone-sulphate. RESULTS: Increases in levels of cortisol, androstenedione and dehydroepiandrosterone after administration of ACTH were greater in testosterone-tre ated transsexual patients than controls. CONCLUSION: We conclude that testosterone increases the response of the adrenal gland to stimulation by ACTH.

PMID: 8013140, UI: 94282949

---

Other Formats:
Links:

Order this document

J Pathol 1993 May;170(1):37-43

An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: a comparison with normal female breast and male breast showing gynaecomastia.

Burgess HE, Shousha S

Department of Histopathology, Charing Cross and Westminister Medical School, London, U.K.

This study was aimed at assessing the effects of therapeutic long-term administration of androgens on normal human female breast. Sections from mastectomy specimens of 29 female-to-male transsexuals who had prolonged androgen administration prior to surgery were examined using routine light microscopy and immunohistochemical techniques. For comparison, sections from ten 'normal' female breast reduction mammoplasty specimens and ten cases of gynaecomastia were similarly examined. Haematoxylin and eosin-stained sections were assessed for the prevalence of elements of the normal breast and benign breast lesions. Immunoperoxidase techniques were performed to study the distribution of a variety of breast-associated antigens and receptors. The results were assessed semi-quantitatively. The prevalence of normal acini and ducts, fibrosis, cysts, and apocrine metaplasia in transsexual specimens was not statistically different from that seen in normal controls. However, transsexual specimens had a significantly higher prevalence of microcalcification than normals. The majority of transsexual specimens were positive for gross cystic disease fluid protein-15, lactoferrin, and progesterone and oestrogen receptors, and negative for B72.3 and pS2. These findings were not significantly different from those in normal controls. All ten gynaecomastia specimens were positive for oestrogen and progesterone receptors. The prevalence of oestrogen receptors was significantly higher than that seen in transsexuals and normal controls, but the prevalence of progesterone receptors was only significantly higher than that seen in transsexuals. It is concluded that long-term androgen administration does not appear to have any significant lasting effect on the normal human female breast, as demonstrated by a wide range of histological and immunohistological criteria.

PMID: 8326458, UI: 93316241

---

Other Formats:
Links:

Order this document

Ann Intern Med 1993 Mar 15;118(6):429-432

Influence of sex hormones on plasma endothelin levels.

Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ

Free University Hospital, Amsterdam, The Netherlands.

OBJECTIVE: To determine whether a sex-associated difference in endothelin levels exists and to assess whether this difference is mediated by sex hormones. DESIGN: Initial survey in healthy persons, followed by a nonrandomized intervention. SETTING: A university teaching hospital. PATIENTS: Twenty-three healthy men, 29 healthy women, 20 pregnant women, and 12 male-to-female and 13 female-to-male transsexual patients. MEASUREMENTS: Plasma levels of endothelin were first assessed in healthy men, healthy women, and pregnant women; subsequently, endothelin levels were determined in male-to-female and female-to-male transsexual patients both before and during cross-gender hormone treatment. This treatment involves administration of testosterone esters to women and of ethynylestradiol and cyproterone acetate to men. RESULTS: Endothelin levels were higher in me n than in women (5.9 +/- 1.2 compared with 4.17 +/- 0.67 pg/mL; P < 0.01). Endothelin levels were lower in pregnant women than in age- and sex-matched nonpregnant controls (2.19 +/- 0.73 compared with 4.17 +/- 0.67 pg/mL; P < 0.01). In 12 male-to-female transsexuals treated with estradiol and the progestational agent cyproterone acetate, endothelin levels decreased from 8.1 +/- 3.0 to 5.1 +/- 2.0 pg/mL (P < 0.01). In 13 female-to-male transsexuals treated with testosterone, endothelin levels increased from 6.2 +/- 1.1 to 7.8 +/- 1.2 pg/mL (P < 0.01). CONCLUSION: Sex hormones may modulate plasma endothelin levels, with male hormones rai sing levels and female hormones lowering them. This finding may be important in explaining sex-associated differences in susceptibility to atherosclerotic cardiovascular disease.

PMID: 8439117, UI: 93175793

---

Other Formats:
Links:

Order this document

Fertil Steril 1992 Sep;58(3):603-608

Effects of ethinyl estradiol on semen quality and various hormonal parameters in a eugonadal male.

Lubbert H, Leo-Rossberg I, Hammerstein J

Hospital for Women, Department of Gynaecological Endocrinology and Reproductive Medicine, Free University of Berlin, Germany.

OBJECTIVE: To determine the influence of estrogens on male fertility. DESIGN: A 36-year-old eugonadal male was subjected to two different regimens of treatment with ethinyl estradiol (EE2). Sperm quality, immunoreactive luteinizing hormone (LH) and follicle-stimulating Hormone (FSH), testosterone (T), estrone (E1), estradiol (E2), dehydroepiandrosterone sulfate (DHEAS), prolactin (PRL) and sex hormone-binding globulin were determined at intervals of 2 weeks for 315 days. SETTING: A gender dysphoria clinic. PATIENT: A transsexual male nurse. MAIN OUTCOME MEASURES: It was hypothesized (and confirmed) that by comparing the effects of increasing and constant dose of EE2 on fertility parameters, differences in estrogen-sensitivity would show more clearly. Furthermore, this procedure served to find the mi nimal dose of EE2 for complete testicular suppression. RESULTS: Low doses of EE2 (20 micrograms/d) had no negative effect on sperm motility and density for a period of approximately 4 weeks, whereas high doses (60 micrograms/d) reduced motility already after a few days and led to a pronounced decrease in sperm density after 2 weeks. After discontinuation of therapy, motility normalized faster than sperm density. Under increasing doses of EE2 there was a constant decrease of FSH that occurred several weeks earlier than that of LH. Under constant dose of EE2 (60 micrograms/d) the decrease of LH was delayed (with respect to FSH) by only a few days. The decrease in T showed a stronger correlation with that of FSH than with that of LH. Volume and fructose content of the seminal fluid correlated with the decrease in T. Rebound effects were observed for FSH, LH, T, and fructose during the therapy& #045;free interval. Ethinyl estradiol therapy had no influence on the serum concentrations of E1, E2, and PRL. Estrone was the dominant estrogen before and after therapy with EE2. Adrenal gland activity was markedly suppressed by EE2, as reflected by the decrease in DHEAS. CONCLUSION: The suppressive effect of EE2 on FSH and sperm motility was more pronounced and consistent than on LH and sperm density. The T decrease appears to be mainly caused by a direct effect of EE2 on the testes.

PMID: 1387850, UI: 92394314

---

Other Formats:
Links:

Order this document

Med Hypotheses 1992 Sep;39(1):85-87

Are all males equal? Anatomic and functional basis for sexual orientation in males.

Elias AN, Valenta LJ

University of California, Irvine 92717.

In non-human primates anterior hypothalamic nuclei are closely involved in heterosexual activity in males. In humans, hypothalamic nuclei which correspond to these nuclei in non-human primates have been shown to have a neuronal density in homosexual men that is approximately half of that seen in heterosexual men. In addition, homosexual men exhibit a positive luteinizing hormone response to acutely administered estrogen that is intermediate between women (flat response) and heterosexual men (exaggerated response). Furthermore, on the basis of serum testosterone concentrations in similarly feminized transsexual males on estrogen/progestogen treatment 3 distinct groups can be identified. It is postulated that anatomic differences in the anterior hypothalamic nuclei that regulate sexual orientation in males may lead to alteration in the gonadotropin releasing hormone (GnRH) pulse/frequency leading to a more female-type pattern of gonadotropin secretion in homosexual males. Based on data in transsexual males this pattern may be more or less of the female-type in subsets of male homosexuals.

PMID: 1331721, UI: 93062278

---

Other Formats:
Links:

Order this document

Clin Endocrinol (Oxf) 1992 Jun;36(6):565-571

17 beta-Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals.

Pache TD, Hop WC, de Jong FH, Leerentveld RA, van Geldorp H, Van de Kamp TM, Gooren LJ, Fauser BC

Department of Obstetrics and Gynaecology, Dijkzigt University Hospital, Rotterdam, The Netherlands.

OBJECTIVE: The aim was to monitor carefully follicular growth arrest in polycystic ovaries by assay of hormones in individual follicles. DESIGN AND PATIENTS: Fluid from follicles less than or equal to 10 mm was obtained from ovaries of 16 regularly cycling women between days 1 and 12 of the follicular phase (controls, n = 120 follicles), polycystic ovaries of five women with polycystic ovary syndrome (n = 43), and polycystic ovaries from 14 long-term testosterone treated female to male transsexuals (n = 120). MEASUREMENTS: Fluid was assayed for oestradiol, androstenedione, and immunoactive inhibin. Luteinizing hormone, follicle-stimulating hormone, and testosterone levels were estimated in serum. RESULTS: Median serum LH was lower in transsexuals than in controls (P less than 0.05), and in polycystic ovary syndrome (P less than 0.01). Med ian serum testosterone was not significantly different between polycystic ovary syndrome and transsexuals, and was elevated in both groups as compared to controls (P less than 0.01). Oestradiol was present in all follicles obtained from polycystic ovaries of polycystic and transsexual patients, in which no follicle greater than 10 mm could be detected. In the three groups, between-patient differences in mean oestradiol, androstenedione, inhibin, and androstenedione/oestradiol ratio were significantly larger than expected in view of the variation between follicles within individuals. Taking into account this between-patient difference, no significant differences could be established between the three groups for all endocrine parameters. The percentage of presumed healthy follicles (androstenedione/oestradiol ratio less than or equal to 4) was 12% in controls, 17% in polycystics, and 14% in transsexuals, and was not significantly different between groups. CONCLUSIONS: The results may indicate that (1) abnormally high circulating androgen concentrations with or without elevated LH levels disturb the process of selection, and could therefore play a role in the pathogenesis of polycystic ovaries; (2) in polycystic ovaries from polycystic ovary syndrome and transsexual patients, aromatase activity is present in vivo in small antral follicles, and the proportion of presumed healthy follicles is not different from that encountered in normal ovaries; (3) oestradiol levels are not different between non-dominant follicles of normal and polycystic ovaries, suggesting that only enhancement of aromatase activity by FSH may be disrupted in polycystic ovaries, (4) because androstenedione levels are not different comparing follicles of normal and polycystic ovaries, hyperandrogenaemia in the syndrome seems to originate from the abnormally high number of cystic atretic follicles generally observed in polycystic ovaries; (5) marked variation in the endocrine follicular microenvironment within and between-women precludes pooling fluid from several follicles.

PMID: 1424181, UI: 93047364

---

Other Formats:
Links:

Order this document

J Natl Med Assoc 1992 Mar;84(3):241-250

Hormone pattern in pharmacologically feminized male transsexuals in the California State prison system.

Valenta LJ, Elias AN, Domurat ES

Patton State Hospital, Department of Mental Health, State of California.

The hormonal profile of 40 transsexual inmates from a pool of 86 inmates in the California State prison system was studied before and after therapy with feminizing hormones. Clinical and social data were obtained on all 86 inmates; the incidence of human immunodeficiency virus (HIV) seropositivity was examined in 76 of the 86 individuals. Despite similar degrees of feminization in all 40 individuals in whom hormonal studies were performed, variable suppression of serum testosterone concentrations was present. Based on their testosterone concentrations while on feminizing hormone therapy, the transsexual inmates could be divided into three groups. In Group I (the "suppressed" group), the serum testosterone concentrations were markedly depressed (less than 10 ng/dL); in Group II (the "non-suppressed" group), the values of testosterone were normal (446 to 1072 ng/dL); an d in Group III (the "intermediate" group), the testosterone values were between those of the suppressed group and the nonsuppressed group. We speculate that feminizing hormone therapy may induce the development of a state of target hormone resistance to testosterone that results in similar degrees of feminization independent of the circulating concentrations of testosterone. The incidence of HIV seropositivity (3/76) was considerably less than anticipated based on previous studies in populations at high risk for developing the acquired immunodeficiency syndrome.

PMID: 1578499, UI: 92251817

---

Other Formats:
Links:

Order this document

Arch Sex Behav 1990 Oct;19(5):507-516

Effect of estrogens on prolactin secretion in transsexual subjects.

Goh HH, Ratnam SS

Department of Obstetrics and Gynecology, National University of Singapore, National University Hospital, Kent Ridge.

The effect of estrogens on the secretion of prolactin in 8 different groups of transsexual subjects was studied. Two different types of estrogens, estradiol or its conjugate and ethinyl estradiol, were used. Different doses and durations of exposure were employed. Plasma levels of prolactin and SHBG after estrogen exposure were compared with corresponding levels before treatment. Results showed that for estrogens to exert an enhancing effect on the secretion of prolactin, three factors needed to be considered: (i) the absolute concentration of estrogen, (ii) the duration of exposure, and (iii) whether levels of SHBG are sufficiently altered to change the concentration of free estrogen. It appears that there exist both time and dose thresholds for effective enhancement of prolactin secretion by estrogen. Estradiol and its conjugate are more likely to induce hyperprolactinemia than ethinyl estradiol. The reduced e ffect of the latter is probably related to its ability to induce large and rapid increases in SHBG binding which probably results in unaltered free estrogen concentration. In the light of this study, treatment of male transsexuals with high doses of estradiol in its conjugate forms must be viewed with caution.

PMID: 2260915, UI: 91083478

---

Other Formats:
Links:

Order this document

Gynecol Endocrinol 1990 Jun;4(2):127-141

Effects of estrogens, clomiphene and castration in a male transsexual with as compared to those without hypersecretion of gonadotropins.

Goh HH, Ratnam SS

Department of Obstetrics and Gynaecology, National University Hospital, National University of Singapore.

A 24-year-old male-to-female transsexual with hypersecretion of gonadotropins was studied with regard to his recovery from sex steroid hormone treatment before his sex change operation and the effects of castration, clomiphene tests and estrogens on the hypersecretion of gonadotropins. Computer-assisted tomography and X-ray results indicated that the possibility that the hypersecretion of gonadotropins was not associated with a pituitary adenoma could not be ruled out. After a period of recovery from previous sex steroid hormone therapy, inappropriately high FSH and LH levels in the presence of normal male levels of testosterone and estradiol were found. The latter normal levels failed to suppress both the FSH and LH levels. From the clomiphene challenge tests carried out before and after the sex reassignment operation, the estradiol infusion studies and treatment with ethinyl estradiol after the sex reassignment operation, it appears t hat the hypersecretion of gonadotropins was responsive to the negative feedback effect of estrogens. However, the sensitivity, especially that of FSH, was very attenuated. Even after 23 weeks of ethinyl estradiol treatment FSH remained well above the upper limit for normal men. The results showed that before his sex change operation the hypersecretion of gonadotropins in the patient was probably under autonomous control. Testicular factors at normal male concentrations appear to have a minimal negative feedback effect on the hypersecretion of gonadotropins. However, hypersecretion of gonadotropins can be suppressed by prolonged exposure to estrogens.

PMID: 2118708, UI: 90372115

---

Other Formats:
Links:

Order this document

Arch Ital Urol Nefrol Androl 1990 Mar;62(1):121-123

[Effects of long-term administration of androgens on the breast in transsexual women].

[Article in Italian]

Godano A, Sapino A, Pietribiasi F, Bussolati G

Ospedale Mauriziano di Torino.

At present the effect on chronic hormonal treatment of normal mammary glands is not known. However, it is thought that high levels of androgens can cause both stromal sclerosis and epithelial atrophy and might provoke fibrocystic mastopathy. The authors describe their own histological studies performed on mammary glands of two women. They underwent mastectomy for transsexualism after prolonged treatment with testosterone.

PMID: 2141705, UI: 90296088

---

Other Formats:
Links:

Order this document

Arch Ital Urol Nefrol Androl 1990 Mar;62(1):107-111

[Male transsexualism and hormonal therapy: radiologic pictures of the breast].

[Article in Italian]

Godano A, Massara D, Grassi G, Genovese MG, Cavallotti GP, Bocchini R

Divisione di Ostetricia e Ginecologia, Ospedale Mauriziano, Torino.

Often the male transsexual takes hormonal drugs, sometimes under medical prescription but most frequently by his personal choice. They wish to obtain a development of mammary gland and the disappearance of hair from facial skin. Prolonged hormonal and incorrect treatments, mainly for too high dosage and absence of association with progesterone, assumption of oestrogens, can cause the growth of mammary tumours. The Authors present the results of a clinical and radiological study on 15 patients, 12 in treated with hormonal drugs for two years and 3 without any therapy.

PMID: 2141702, UI: 90296085

---

Other Formats:
Links:

Order this document

Br J Psychiatry 1990 Feb;156:285-286

Psychosis in a transsexual.

Faulk M

Publication Types:

• Comment
• Letter

Comments:

• Comment on: Br J Psychiatry 1989 Aug;155:257-9

PMID: 2317639, UI: 90199389

---

Other Formats:
Links:

Order this document

Metabolism 1989 Sep;38(9):869-873

Mortality and morbidity in transsexual patients with cross-gender hormone treatment.

Asscheman H, Gooren LJ, Eklund PL

Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands.

Sex steroid treatment is associated with side effects. The number of deaths and morbidity cases in 425 transsexual patients treated with cross-gender hormones were evaluated retrospectively and compared with the expected number in a similar reference group of the population. The number of deaths in male-to-female transsexuals was five times the number expected, due to increased numbers of suicide and death of unknown cause. Combined treatment with estrogen and cyproterone acetate in 303 male-to-female transsexuals was associated with a 45-fold increase of thromboembolic events, hyperprolactinemia (400-fold), depressive mood changes (15-fold), and transient elevation of liver enzymes. Androgen treatment in 122 female-to-male transsexuals was associated with weight increase greater than 10% (17.2%) and acne (12.3%). In both groups persistent liver en zyme abnormalities could be attributed to other causes than sex steroids (hepatitis B and alcohol abuse). Much of the morbidity was minor and reversible with appropriate treatment or temporary discontinuation of hormone treatment. Thus, the dilemma of prescribing cross gender hormones in view of the needs of these patients is not resolved. Explanation of possible side effects and careful clinical judgment remain the cornerstone of the clinical decision to prescribe cross-gender hormones. Furthermore, follow up of this relatively young population to disclose long-term side effects and to elucidate the association of sex steroids with coronary heart disease, as well as efforts to reduce the risk of thromboembolic events, are required.

PMID: 2528051, UI: 89364275

---

Other Formats:
Links:

Order this document

J Endocrinol Invest 1989 Jul;12(7):449-454

Exogenous estrogen effect on lipid/lipoprotein cholesterol in transsexual males.

Damewood MD, Bellantoni JJ, Bachorik PS, Kimball AW Jr, Rock JA

Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Lipid/lipoprotein cholesterol values and sex-hormone-binding globulin levels were determined in 40 transsexual males aged 20-38, 20 castrated and 20 non-castrated, taking conjugated estrogens to induce female characteristics. Variables controlled included dose of estrogen, age, weight, smoking, alcohol intake, exercise and diet history. Transsexual males on estrogens had significantly higher mean (+/- SE) HDL cholesterol levels (69.0 +/- 7.1 mg/dl) respectively, for castrated males and (53.8 +/- 6.2 mg/dl) for non-castrated males, respectively compared to normal control males not on hormonal therapy (41.5 +/- 5.4) (p less than 0.001), regardless of dose of estrogen received. The total cholesterol/HDL ratio was 3.31-4.05 in transsexual males on estrogens compared to 5.03 for normal males (p less than 0.001). Transsexual males had mean SHBG levels in the female range (63.4 to 71.8 nmol/ml), significantly higher than controls (26.7 nmol/ml) (p less than 0.001). SHBG levels were correlated with estrogen use, dose and HDL cholesterol levels. We conclude that exogenous estrogens administered to transsexual males results in a female pattern of lipid/lipoprotein cholesterol and SHBG concentration. The decreased total cholesterol/HDL ratio may imply a lower atherogenic potential and a lessened cardiovascular risk in males who take estrogens.

PMID: 2794371, UI: 90009891

---

Other Formats:
Links:

Order this document

J Clin Endocrinol Metab 1989 Jul;69(1):151-157

The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects.

Spinder T, Spijkstra JJ, van den Tweel JG, Burger CW, van Kessel H, Hompes PG, Gooren LJ

Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands.

Polycystic ovarian disease (PCOD) is associated with elevated serum LH and (sub)normal FSH levels, while serum androgen levels are often elevated. To clarify the role of androgens in this abnormal pattern of gonadotropin secretion, LH secretion was studied in 1) 9 eugonadal female to male transsexual subjects before and during long term (6 months) testosterone (T) administration (250 mg/2 weeks, im), and 2) in a woman with an androgen-secreting ovarian tumor both before and after surgical removal of the tumor. Finally, we studied the effects of high serum androgen levels on ovarian histology in 3) 26 transsexual subjects after long term (9-36 months) T administration (250 mg/2 weeks, im) to assess whether T-induced ovarian abnormalities are similar to those that occur in women with PCOD. Long term T treatment in the nine female to male transsexual subje cts resulted in increases in the mean serum T level from 1.7 +/- 0.8 (+/- SD) to 40.8 +/- 31.9 nmol/L (P less than 0.01), the mean serum dihydrotestosterone level from 0.6 +/- 0.2 to 3.3 +/- 1.5 nmol/L (P less than 0.02), and the mean serum free T level from 9.5 +/- 5.2 to 149 +/- 46 pmol/L (P less than 0.02). Mean serum estrone and estradiol levels were similar before and during T treatment. The mean serum LH level decreased from 6.3 +/- 2.0 to 2.9 +/- 1.1 U/L (P less than 0.01), and the mean FSH levels decreased from 6.6 +/- 2.0 to 3.7 +/- 2.2 U/L (P less than 0.02). Pulsatile LH secretion before and during T treatment was studied in five subjects. Neither the mean nadir LH interval nor the LH pulse amplitude changed significantly in these five subjects. The serum T level in the woman with the androgen-secreting ovarian tumor was 9.6 nmol/L, and it declined to normal after removal of the tumor. Her mean serum LH and FSH levels, the mean nadir LH interval, and LH pulse amplitude were in the normal range before and after removal of the tumor. Studies of ovarian histopathology in 26 transsexual subjects after long term androgen treatment revealed multiple cystic follicles in 18 subjects (69.2%), diffuse ovarian stromal hyperplasia in 21 subjects (80.8%), collagenization of the tunica albuginea in 25 subjects (96.2%), and luteinization of stromal cells in 7 subjects (26.9%). Findings consistent with criteria for the pathological diagnosis of polycystic ovaries, that is 3 of the 4 findings listed above, were present in 18 of the 26 subjects (69.2%).

PMID: 2471710, UI: 89278278

---

Other Formats:
Links:

Order this document

Arch Sex Behav 1989 Feb;18(1):49-57

Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism.

Prior JC, Vigna YM, Watson D

Department of Medicine (Endocrinology), University of British Columbia, Vancouver General Hospital, Canada.

The clinical and hormonal response to 12-month therapy with the antiandrogen, spironolactone, in conjunction with near-physiologic doses of female gonadal steroids in 50 transsexual males, is presented. An unselected referred series of 61 men with the psychiatric diagnosis of transsexualism was treated; 10 subjects who had received previous gonadal surgery and 1 man with Klinefelter's syndrome were excluded. Twenty-seven conventionally treated (CT; high-dose estrogen), age 34.4 +/- 10.5 years, mean +/- SD, and 23 untreated patients (SPS), age 30.7 +/- 6.2 years, were studied. Following the initial visit, all 50 were begun on spironolactone and low-dose female hormone therapy. Despite high-dose estrogen treatment for more than 2 years, the mean testosterone (T) level for the CT group was not in the f emale range (169 +/- 193 ng/dl; normal 20-80). Spironolactone, in doses of 200-600 mg/day, lowered T to the female range in both groups after 12 months (CT 87 +/- 111 and SPS 49 +/- 41 ng/dl). This was achieved in the CT group despite decreases in estrogen dose and discontinuation of parenteral therapy. SPS subjects experienced significant decreases in plasma T (642 +/- 236 to 49 +/- 41 ng/dl, p less than 0.001). Systolic blood pressure dropped (128 +/- 14 to 121 +/- 14 mm Hg, p less than 0.05). The clinical response, including decreased male pattern hair, breast development, feminization, and lack of erections was excellent in most subjects.

PMID: 2540730, UI: 89227588

---

Other Formats:
Links:

Order this document

Sb Lek 1989 Jan;91(1):16-20

[Comparison of the excretion of 3 androgens registered in Czechoslovakia].

[Article in Czech]

Hampl R, Hana V, Heresova J, Brzek A, Marek J, Starka L

Hypogonadal men of different aetiology were administered testesterone undecanoate (Andriol, Organon) and methyltestosterone (Agovirin coated tablets, Spofa) for three months alternatively. By means of specific radioimmunoassays excretion of testosterone and methyltestosterone respectively in the urine was observed in 20 and 5 patients respectively. The course of excretion of both the preparations is possible to illustrate by decreasing curves with apparent half-lives 1.74 and 3.90 day respectively. Analogous observation of testosterone excretion after three-month administration of testosterone isobutyrate (Agovirin depot) to five female-to-male transsexual patients was observed. Excretion course shows the maximum on 27th day after the treatment was discontinued and it is not possible to illustrate it by a monotonous curve.

PMID: 2717876, UI: 89241913

---

Other Formats:
Links:

Order this document

Psychoneuroendocrinology 1989;14(1-2):97-102

Pulsatile luteinizing hormone release and ovarian steroid levels in female-to-male transsexuals compared to heterosexual women.

Spinder T, Spijkstra JJ, Gooren LJ, Burger CW

Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands.

It has been suggested that there is a difference in the interaction between sex steroids and gonadotropin secretion between transsexual and heterosexual women. In this study we tested whether there is a difference in the pulsatile release characteristics of luteinizing hormone (LH) and in ovarian steroid concentrations between 16 female-to-male (f-to-m) transsexuals and eight eugonadal heterosexual women during the early follicular phase of the menstrual cycle. Blood samples for LH determination were collected every 10 min for 7 hr in the transsexual group, and every 10 min for 6 hr in the heterosexual group. There were no significant differences between the transsexual and heterosexual group in mean serum LH concentration (6.9 +/- 2.4 U/l vs. 7.5 +/- 2.6 U/l), mean LH nadir interval (77 +/- 37 min vs. 70 +/- 16 min), and mean LH pulse amplitude (2.9 +/- 1.1 U/l vs. 3.0 +/- 1.1 U/l). Serum estrone, 17-beta-estradiol, testosterone, progesterone and FSH concentrations also did not differ between the two groups. There also was not a higher prevalence of polycystic ovarian disease in our f-to-m transsexual group than in the general population.

PMID: 2499904, UI: 89283123

---

Other Formats:
Links:

Order this document

Clin Plast Surg 1988 Jul;15(3):471-487

Transsexual surgery in the genetic female.

Gilbert DA, Winslow BH, Gilbert DM, Jordan GH, Horton CE

Department of Plastic Surgery, Eastern Virginia Medical School, Norfolk.

The increasing acceptance of the transsexual patient by society as well as a willingness of insurance companies to compensate for associated surgical procedures will result in an increase in patients presenting for sex reassignment. Data from gender identity centers suggest that the multidisciplinary approach leads to the best therapeutic results. Significant advances in phalloplasty techniques are yielding genitalia with more normal function and appearance.

Publication Types:

• Review
• Review, tutorial

PMID: 3292116, UI: 88270842

---

the above reports in Macintosh PC UNIX Text HTML
documents on this page through Loansome Doc

---

Books

Amazon.com is pleased to have Confluence Publications in the family of Amazon.com associates. We've agreed to ship books and provide customer service for orders we receive through special links from Confluence Publications.

Amazon.com associates list selected books in an editorial context that helps you choose the right books. We encourage you to visit Confluence Publications often to see what new books they've selected for you.

Thank you for shopping with an Amazon.com associate.

Jeff Bezos
President
Amazon.com Books

P.S. We guarantee you the same high level of customer service you would receive at Amazon.com. If you have a question about an order you've placed, please don't hesitate to contact us.

Basic Endocrinology

Endocrinology by Mac Hadley

Hadley provides an comprehensive coverage of endocrinology, centralizing on the critical roles of chemical messengers and hormones--whether they are of endocrine or neural origin--in the control of physiological processes. This up-t o-date Fourth Edition depicts, through demonstration, the entire human endocrine system in examples designed specifically for premedical and related professional courses. Hadley examines several recently discovered hormones--including their origin , biosynthesis, chemistry, secretion, circulation and metabolism, physiological roles, control of secretion, mechanisms of action and pathophysiology.

The Virility Factor: Masculinity Through Testosterone, the Male Sex Hormone by Robert Bahr

Advanced Endocrinology

Technical references are generally expensive and special-order. If you are interested, you can search for all books on endocrinology.

Of General Interest to Transsexuals

Body Alchemy : Photographs by Loren Cameron

Body Alchemy: Transsexual Portraits is photographer Loren Cameron's intensely personal photo documentary of female-to-male transsexuals (FTMs). A transsexual himself, Loren Cameron brings a sensitive, sophisticated insider's eye to his subject matter. Using documentary style, a series of before-and-after photographs of FTMs in Cameron's transsexual community, his own striking self-portraits, and intimate autobiographical text, he invites the viewer to experience this transformational rite of passage. Body Alchemy includes intimate, narrative photographs of Loren and his partner, Kayt, a lesbian-identified woman whose relationship to Cameron affords her much to say about the fluidity of gender and queer identity. Finally, Body Alchemy includes photographs of genital reconstructions, accompanied by text from three anonymous FTMs who discuss how they feel about their surgeries. Andy Warhol, Robert Mapplethorpe, Dianne Arbus among many others have all trained their lenses on the transgendered figure. Never have the transgendered seriously photographed their own. Not until Loren Cameron, that is.

Ftm : Female-To-Male Transsexuals in Society by Holly Devor

Holly Devor spent many years compiling indepth interviews and researching the lives of transsexual and transgendered people, many of whom became her friends. She traces the everyday and significant events that coalesce in transsexual identity, culminating in gender and sex transformation. After an introduction which grounds the discussion in historical and theoretical contexts, the author takes a life course approach to understanding female-to-male transsexualism. Using her subjects' own words as illustrations, Devor looks at how childhood, adolescent, and adult experiences with family members, peers, and lovers work to shape and clarify female-to-male transsexuals' images of themselves as people who should be men.

Gender Outlaw: On Men, Women, and the Rest of Us by Kate Bornstein

Kate Bornstein has been through some changes--a former heterosexual male, one-time Scientologist and IBM salesperson, now a lesbian woman writer and actress. In this work, she covers everything readers want to know about gender (but are too confused to ask) and takes a witty, incisive look at the radical new politics of sexuality and gender. Also includes Bornstein's play, Hidden: A Gender

Sex Changes : The Politics of Transgenderism by Pat Califia

Pat Califia needs no introduction for lesbian and gay readers. Her writings on sexuality, pornography, censorship, S/M, and other controversial topics have earned her the reputation of a fearless defender of the rights of sexual minorities -- and a fearless intellectual adversary. Sex Changes: The Politics of Transgenderism is Califia's honest, meticulously researched analysis of the contemporary history of transsexuality. Based on in-depth interviews with gender transgressors who "opened their lives, minds, hearts, and bedrooms to the gaze of strangers," Sex Changes demonstrates Pat Califia's hallmark candor and insight. Writing about both male-to-female and female-to-male transsexuals, Califia examines the lives of early transgender pioneers like Christine Jorgenson, Jan Morris, Renee Richards and Mark Rees; partners of transgendered people like Minnie Bruce Pratt; and contemporary transgender activists like Leslie Feinberg and Kate Bornstein. Includes bibliography, resources, index. Pat Califia is well-known as a sharp critic of repressive American attitudes toward gender, sexuality and pornography. She is the author of many books, including Public Sex: The Culture of Radical Sex. Califia lives in San Francisco, where she works as a therapist, primarily serving the gay/lesbian and transgendered communities.

Read My Lips : Sexual Subversion and the End of Gender by Riki Anne Wilchins

Over the course of the past decade transgender politics have become the cutting edge of sexual liberation. While the sexual and political freedom of homosexuals has yet to be fully secured, questions of who is sleeping with whom pale in the face of the battle by transgender activists to dismantle the idea of what it means to be a man or a woman. Riki Anne Wilchins's Read My Lips is a passionate, witty, and extraordinarily intelligent look at how society not only creates men and women--ignoring the fluidity of maleness and femaleness in most people--but also explains how those categories generate crisis for most individuals. It is impossible to read Wilchins's ideas and not be provoked in fundamental and mysterious ways.

Transgender Care : Recommended Guidelines, Practical Inforrmation, and Personal Accounts by Gianna Israel, Donald Tarver

By empowering clients to be well-informed medical consumers and by delivering care providers from the straitjacket of inadequate diagnostic standards and stereotypes, this book sets out to transform the nature of transgender care. In an accessible style, Gianna Israel and Donald Tarver discuss the key mental health issues, with much attention to the vexed relationship between professionals and clients. They propose a new professional role, that of "Gender Specialist." The book contains a wealth of practical information and accounts of people's experiences about coming out to one's employer or to one's friends or spouse. Several essays spell out the legal rights of transgender people with regard to insurance, work, marriage, and the use of rest rooms. The second part of the book consists of thirteen essays on a range of controversial topics.

Transsexuals: Candid Answers to Private Questions by Ramsey Gerald, Phd

This is a great resource book for anyone trying to decide if they are really female-to-male or not. For those getting ready to step out of the closet this book will likely answer many of the questions your going to be asked by family and friends. It is also loaded with facts and figures, a detailed description of what to expect when going to a Gender Identity committee for the first time, and a complete listing of the Standards of Care by the Harry Benjamin International Gender Dysphoria Association, Inc.

Other Web Sites

FTM International

http://www.ftm-intl.org

Gonadotrope Cytochemistry by Gwen Childs, PhD

http://cellbio.utmb.edu/childs/gon1.htm

Medline Search by the National Institute of Health

http://www.ncbi.nlm.nih.gov/Entrez/medline.html

RXMed

http://www.rxmed.com

Standards of Care by the Harry Benjamin International Gender Dysphoria Association

http://www.symposion.com/ijt/ijtc0405.htm

U.S. FDA Personal Use Import Policy by the Cognitive Enhancement Research Institute

http://www.ceri.com/import.htm

United States Pharmacopeia

http://www.usp.org